Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The HiLOG Trial: Ofatumumab, HDMP, and Lenalidomide in Untreated CLL/SLL
NCT01496976Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2012
- Primary completion
- Oct 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab and lenalidomide in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Moffitt Cancer Center. Primary endpoints: Complete Response at 3 months and Partial Response at 3 months. Started Mar 2012; status: completed.
02
Drugs
ofatumumablenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01496976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01496976.